Last $22.19 USD
Change Today -0.04 / -0.18%
Volume 181.7K
HPTX On Other Exchanges
Symbol
Exchange
HPTX is not on other exchanges.
As of 12:44 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

hyperion therapeutics inc (HPTX) Snapshot

Open
$22.55
Previous Close
$22.23
Day High
$22.55
Day Low
$21.70
52 Week High
02/28/14 - $32.98
52 Week Low
12/18/13 - $19.45
Market Cap
459.9M
Average Volume 10 Days
213.1K
EPS TTM
$0.28
Shares Outstanding
20.7M
EX-Date
--
P/E TM
78.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for HYPERION THERAPEUTICS INC (HPTX)

hyperion therapeutics inc (HPTX) Related Bloomberg News

View More Bloomberg News

hyperion therapeutics inc (HPTX) Related Businessweek News

No Related Businessweek News Found

hyperion therapeutics inc (HPTX) Details

Hyperion Therapeutics, Inc., a commercial biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. The company’s products include RAVICTI, which is used as a nitrogen-binding agent for chronic management of adult and pediatric urea cycle disorder (UCD) patients greater than two years of age, who cannot be managed by dietary protein restriction and/or amino acid supplementation alone; and BUPHENYL, an FDA-approved therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California.

54 Employees
Last Reported Date: 03/7/14
Founded in 2006

hyperion therapeutics inc (HPTX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $575.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $347.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $375.0K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $347.0K
Chief Legal & Compliance Officer, Senior Vice...
Total Annual Compensation: $195.9K
Compensation as of Fiscal Year 2013.

hyperion therapeutics inc (HPTX) Key Developments

Hyperion Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 09:10 AM

Hyperion Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 09:10 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Jeffrey S. Farrow, Chief Financial Officer, Principal Accounting Officer and Secretary.

Bruce F. Scharschmidt Intends to Step Down as Chief Medical and Development Officer of Hyperion Therapeutics, Inc

Hyperion Therapeutics, Inc. announced that Bruce F. Scharschmidt, intends to step down from his full time position as the Company's Chief Medical and Development Officer and will transition to the position of Emeritus Chief Medical Officer. Dr. Scharschmidt is expected to transition to his Emeritus role in the middle of next year.

Hyperion Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reports Impairment of Goodwill for the Third Quarter Ended September 30, 2014; Reaffirms Earnings Guidance for 2014

Hyperion Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $26.2 million against $15.5 million a year ago. Loss from operations was $28.8 million against income from operations of $0.5 million last year. Loss before income taxes was $29.8 million against income before income taxes of $0.1 million last year. Net loss was $32.8 million or $1.59 per basic and diluted share against net income of $0.1 million or $0.01 per basic and diluted share last year. Adjusted net income was $1.2 million or $0.05 per diluted share against $3.2 million or $0.15 per diluted share last year. Net revenue was from the sales of its two products for the treatment of urea cycle disorders, RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid and BUPHENYL(R) (sodium phenylbutyrate) Tablets and Powder. For the nine months, the company reported total revenues of $82.8 million against $23.6 million a year ago. Loss from operations was $10.9 million against $14.3 million last year. Loss before income taxes was $12.3 million against income before income taxes of $16.2 million last year. Net loss was $13.4 million or $0.66 per basic and diluted share against net income of $16.2 million or $0.79 per diluted share last year. Adjusted net income was $25.9 million or $1.19 per diluted share against adjusted net loss of $9.5 million or $0.50 per basic and diluted share last year. For the quarter, impairment of goodwill was $30.2 million. In September 2014, Hyperion announced that it is terminating the development of DiaPep277 after completing the ongoing Phase 3 clinical trial as a result of evidence that was uncovered that certain employees of Andromeda engaged in serious misconduct including collusion with a third party biostatistics firm in Israel to improperly receive un-blinded DIA-AID 1 trial data and to use such data to obtain favorable results in the trial. As a result, the company recorded a $30.2 million impairment charge in the third quarter of 2014 related to the Andromeda acquisition. The company reiterated its 2014 revenue guidance and continues to anticipate total net revenues to be in the range of $105 million to $110 million. The company anticipates total net revenues for RAVICTI to range from $89 million to $93 million and BUPHENYL net revenues to range from $16 million to $17 million. The company is revising its adjusted 2014 operating expense, R&D and SG&A guidance downward, from the previously issued guidance of $66 million to $78 million and now anticipates it to be in the range of $64 million to $70 million which excludes amortization expense, stock-based compensation expense, and impairment charges related to the Andromeda acquisition. The company continues to expect amortization expense to be approximately $4 million to $5 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HPTX:US $22.19 USD -0.04

HPTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HPTX.
View Industry Companies
 

Industry Analysis

HPTX

Industry Average

Valuation HPTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.4x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HYPERION THERAPEUTICS INC, please visit www.hyperiontx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.